View More Recent Stories

Dec 30, 2024 05:17PM Acadia Pharma (ACAD) to Join S&P SmallCap 600
Nov 27, 2024 07:12AM Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD), SAN711 deal is 'incrementally positive'
Nov 26, 2024 04:07PM Acadia Pharma (ACAD) Enters Exclusive License Agreement with Saniona for SAN711
Nov 20, 2024 04:34PM Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause
Nov 6, 2024 04:07PM Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance
Nov 5, 2024 04:06PM Acadia Pharma (ACAD) to Sell Rare Pediatric Disease Priority Review Voucher for $150M
Oct 17, 2024 06:17AM Guggenheim Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
Oct 16, 2024 04:07PM Acadia Pharma (ACAD) Announces Health Canada Approval of DAYBUE for the Treatment of Rett Syndrome
Oct 10, 2024 08:25AM Raymond James Resumes Acadia Pharmaceuticals (ACAD) at Market Perform
Sep 27, 2024 07:11AM BMO Capital Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
Sep 23, 2024 04:16PM Acadia Pharma (ACAD) Appoints Catherine Owen Adams as New CEO
Aug 7, 2024 07:40AM Acadia Pharmaceuticals (ACAD) PT Lowered to $28 at Needham
Aug 7, 2024 06:24AM Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital
Aug 7, 2024 03:35AM Morgan Stanley Downgrades Acadia Pharmaceuticals (ACAD) to Equalweight
Aug 6, 2024 04:08PM Acadia Pharma (ACAD) Tops Q2 EPS by 2c, provides guidance
Jul 18, 2024 09:05AM Acadia Pharma (ACAD): Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating DAYBUE in Patients with Rett Syndrome Published
Jul 16, 2024 07:18AM TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
Jun 26, 2024 04:05PM BMO Capital Starts Acadia Pharmaceuticals (ACAD) at Outperform
Jun 18, 2024 09:04AM Acadia Pharma (ACAD) Presents DAYBUE Real-World Evidence and Additional Data in Rett Syndrome
View More Recent Stories